Low-cost anti-HIV compounds: potential application for AIDS therapy in developing countries

Area of Science:

• Pharmacology
• Infectious Diseases
• Global Health

Background:

• High cost of current Acquired Immunodeficiency Syndrome (AIDS) drugs limits access, particularly in developing nations.
• The average annual cost of AIDS therapy in the USA ($22,000) is prohibitive for many, including uninsured patients.
• A significant majority (95%) of Human Immunodeficiency Virus (HIV)-infected individuals reside in developing countries.

Purpose of the Study:

• To review the development and discovery of affordable anti-HIV drugs.
• To explore the potential of existing, over-the-counter pharmaceuticals for HIV treatment.
• To identify cost-effective therapeutic options for global HIV/AIDS management.

Main Methods:

• Literature review of existing pharmaceuticals with potential anti-HIV activity.
• Analysis of immunomodulating substances for their efficacy against HIV.
• Discussion of clinical applications and potential combination therapies.

Main Results:

• Several existing drugs and immunomodulating substances show anti-HIV activity.
• Compounds like warfarin, cimetidine, levamisole, acetaminophen, gramicidin, and V-1 immunitor are identified as potential candidates.
• These agents may be suitable for use in combination drug regimens.

Conclusions:

• Repurposing existing pharmaceuticals offers a feasible and economical approach to developing affordable AIDS drugs.
• Identified compounds demonstrate potential for effective HIV treatment, improving accessibility.
• Combination therapy using these affordable agents could enhance treatment outcomes for HIV-infected patients globally.